Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $61.58 Consensus PT from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $61.58.

A number of equities analysts have recently issued reports on NTLA shares. Royal Bank of Canada reduced their target price on shares of Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Citigroup dropped their target price on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Friday, May 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Intellia Therapeutics in a report on Monday, June 24th. JPMorgan Chase & Co. lowered their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Finally, StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th.

Intellia Therapeutics Trading Down 1.6 %

NASDAQ NTLA opened at $21.27 on Monday. Intellia Therapeutics has a 1-year low of $19.37 and a 1-year high of $38.71. The company has a 50 day moving average of $23.75 and a 200-day moving average of $24.84. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -3.97 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. During the same period last year, the firm posted ($1.40) EPS. The business’s revenue was down 48.5% on a year-over-year basis. On average, analysts forecast that Intellia Therapeutics will post -5.19 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

A number of large investors have recently made changes to their positions in the company. ARK Investment Management LLC lifted its stake in Intellia Therapeutics by 5.5% in the second quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company’s stock valued at $259,514,000 after buying an additional 606,507 shares in the last quarter. Vanguard Group Inc. boosted its stake in Intellia Therapeutics by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after purchasing an additional 746,263 shares during the period. Federated Hermes Inc. boosted its stake in Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock worth $51,494,000 after purchasing an additional 371,189 shares during the period. Dimensional Fund Advisors LP increased its holdings in Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock worth $29,648,000 after purchasing an additional 98,865 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC raised its stake in shares of Intellia Therapeutics by 8.4% in the 1st quarter. Chevy Chase Trust Holdings LLC now owns 1,074,610 shares of the company’s stock valued at $29,563,000 after purchasing an additional 83,435 shares during the period. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.